Posted by Michael Wonder on 18 Apr 2022
China NMPA approves tislelizumab for patients with second-line oesophageal squamous cell carcinoma
15 April 2022 - Tislelizumab is now approved for eight indications in China.
BeiGene today announced that the China NMPA has granted approval to BeiGene’s anti-PD-1 antibody, tislelizumab, as a treatment for patients with locally advanced or metastatic oesophageal squamous cell carcinoma who have disease progression or are intolerant to first-line standard chemotherapy.
